Watch Live

Tweet TWEET

Psivida Says Renegotiates Licensing Agreement With Pfizer

Psivida Corp. (PSDV) has renegotiated its pact with Pfizer Inc. (PFE) to focus on the development of sustained- release implant to deliver Latanoprost for ocular hypertension and glaucoma, according to a regulatory filing.

To contact the reporter on this story: Tim Smith in Sydney at tsmith58@bloomberg.net

To contact the editor responsible for this story: Tim Smith at tsmith58@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.